


CORRECTION



## Correction: An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies

Eleonora Orlando<sup>1,2</sup> · Matúš Medo<sup>1,2</sup> · Ariel Bensimon<sup>3</sup> · Aurélie Quintin<sup>1,2</sup> · Rahel Riedo<sup>1,2</sup> · Selina M. Roth<sup>1,2</sup> · Carsten Riether<sup>4,5</sup> · Thomas M. Marti<sup>6,7</sup> · Daniel M. Aebersold<sup>1,2</sup> · Michaela Medová<sup>1,2</sup> · Ruedi Aebersold<sup>3,8</sup> · Yitzhak Zimmer<sup>1,2</sup> 

Accepted: 13 February 2023  
© The Author(s) 2023

**Correction: Cellular and Molecular Life Sciences**  
**(2022) 80:6**  
<https://doi.org/10.1007/s00018-022-04634-2>

The original article has been updated.

In the published article reference 41 was missed in the third paragraph, under discussion section in the page 15, and the below mentioned reference has been incorrectly processed, and the error in the below references has been now updated. Previously, we have reported that aberrant activation of the MET receptor modulates the cellular response to IR by rewiring key DNA damage response (DDR)-related phosphorylations in some tumor cell lines featuring MET activation [41]. Assuming that a MET–DDR interface underlies MET dependency, here we monitored 116 DDR- and RTK signalling-associated phosphosites in a panel of MET-positive, MET-responsive as well as non-responsive tumor models following targeted MET inhibition. This analysis revealed 14 METi-modulated phosphorylation events that were present solely in MET-addicted models, thus representing ‘MET-asa-driver’ footprints.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

### References

1. Weinstein IB (2002) Cancer. Addiction to oncogenes—the Achilles heal of cancer. *Science* 297:63–64
38. Zagorac I et al (2018) In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer. *Nat Commun* 9:3501

The original article can be found online at <https://doi.org/10.1007/s00018-022-04634-2>.

✉ Ruedi Aebersold  
aebersold@imsb.biol.ethz.ch

✉ Yitzhak Zimmer  
yitzhak.zimmer@insel.ch

<sup>1</sup> Department of Radiation Oncology, Inselspital, Bern University Hospital and University of Bern, Bern, Switzerland

<sup>2</sup> Department for BioMedical Research, Radiation Oncology, University of Bern, MEM-E807, Murtenstrasse 35, 3008 Bern, Switzerland

<sup>3</sup> Department of Biology, Institute of Molecular Systems Biology, ETH Zürich, HPM H25, Otto-Stern-Weg 3, 8093 Zurich, Switzerland

<sup>4</sup> Tumorimmunology, Department for BioMedical Research, University of Bern, Bern, Switzerland

<sup>5</sup> Department of Medical Oncology, Inselspital, University Hospital and University of Bern, 3010 Bern, Switzerland

<sup>6</sup> Thoracic Surgery, Department for BioMedical Research, University of Bern, Bern, Switzerland

<sup>7</sup> Division of General Thoracic Surgery, Inselspital Bern University Hospital, Bern, Switzerland

<sup>8</sup> Faculty of Science, University of Zürich, Zurich, Switzerland

49. Lange V, Picotti P, Domon B, Aebersold R (2008) Selected reaction monitoring for quantitative proteomics: a tutorial. *Mol Syst Biol* 4:222
67. Minari R et al (2021) Afatinib therapy in case of EGFR G724S emergence as resistance mechanism to osimertinib. *Anticancer Drugs* 32:758–762
69. Bardelli A et al (2013) Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. *Cancer Discov* 3:658–673
73. Huang S, Peter Rodemann H, Harari PM (2016) Molecular targeting of growth factor receptor signaling in radiation oncology. *Recent Results Cancer Res* 198:45–87
77. Glück AA et al (2018) Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1 $\alpha$  levels under hypoxia. *Oncogene* 37:4181–4196
89. Wang Z et al (2022) Proteomic and phosphoproteomic analyses reveal the oncogenic role of PTK7-NDRG1 axis in non-small-cell lung cancer cell resistance to AZD9291. *ACS Chem Biol* 17:2849–2862

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.